Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Expands Hep C Agreement With Three Rivers To China

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Three Rivers Pharmaceuticals has signed a definitive licensing agreement with Amgen to acquire further commercial rights, including China, for the hepatitis C drug Infergen, the company announced Sept. 1

You may also be interested in...

China’s HCV Drug Market To Grow To $150 Million By 2012

SHANGHAI - China's hepatitis C virus drug market will grow to $150 million by 2012, according to a report released in September by Decision Resources

Amgen and India’s Jubilant In Drug Discovery Partnership

MUMBAI - Jubilant Biosys, a subsidiary of Indian contract research and manufacturing services provider Jubilant Organosys, has entered into a drug discovery partnership with Amgen to develop a portfolio of new drugs across various therapeutic areas

Takeda Makes $1 Billion Move For Amgen Development Rights

Eyeing the looming 2011 patent expiration of its top-seller Actos (pioglitazone), Takeda has acquired exclusive Japanese development and commercialization rights, and in one case global rights, to 13 of Amgen's clinical candidates, at a potential cost of up to $1.2 billion




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts